SAYPHA VOLUME LIDO (1x1ml) CROMA

SAYPHA VOLUME LIDO (1x1ml)/EX PRINCESS VOLUME LIDO (1x1ml) CROMA

IN 2019 CROMA PRINCESS BECOMES CROMA SAYPHA. MEDICALE USE. CE Marked Medical Device class III. SMART - a unique method of cross–linking created by CROMA.

DESCRIPTION SAYPHA VOLUME LIDOCAINE

SAYPHA VOLUME LIDOCAINE is a highly cross-linked, sterile,viscoelastic, biodegradable, monophasic hyaluronic acid gel filler which is best used to correct deep wrinkles, folds and scarring, for facial contouring and building volume. SAYPHA VOLUME LIDOCAINE is a clear, colourless, isotonic and homogenized injectable gel implanted is injected in the deep dermis with a 27G1/2 needle, it is available with or without the addition of lidocaine for additional comfort during treatment. It consists of cross-linked hyaluronic acid, formulated to a concentration of 23 mg/ml in a physiologic buffer. TECHNOLOGY S. M. A. R. T. : The hyaluronic acid in SAYPHA VOLUME LIDOCAINE is cross-linked using Supreme Monophasic and Reticulated Technology S.M.A.R.T.

SAYPHA VOLUME LIDOCAINE by CROMA DETAILS

• Concentration HA : 2.3 % (23 mg/mL).
• Lidocaine :  0,3%.
• Reticulating agent : BDDE 3/4.
• Other ingredients : Phosphate-buffer, NaCL
• Dynamic viscosity (at shear rate 2 s-1: ) : 90.000 – 135.000 mPa.s.
• Needle: 2 x 27G 1⁄2 thin-wall needles.
• Packaging : Box of 1 mL syringe.
• Injection area : Deep dermis or subcutis.
• Indication : Viscoelastic solution for the correction of deep wrinkles and folds, to increase or restore facial volume, and to shape the facial contours.
• Estimated duration in the skin: At least 9 months.

PACKAGING SAYPHA VOLUME LIDOCAINE

• 1 x 1ml : Box of 1 ml pre-filled syringe.
• Needles : 2 X 27 G1/2 thin wall Terumo needles ( CE 0197).
• Two traceability labels.

INDICATION SAYPHA VOLUME LIDOCAINE

• VOLUMISING ACTION.
• SAYPHA VOLUME LIDOCAINE  is indicated for the correction of deep wrinkles and folds, cutaneous depressions, facial contours and the creation of volume.
• Deep and volumetric treatments.
• Viscoelastic solution for the correction of deep wrinkles and folds, to increase facial volume, and to shape and remodel the facial contours.
• To adress reconstructive purposes in the treatment of facial lipoatrophy, debilitating scars or morphological asymetry.

COMPOSITION SAYPHA VOLUME LIDOCAINE

Cross-linked BDDE 3/4 HA 2.3 % (23 mg/mL) + Lidocaine 0,3% : 

• It consists of cross-linked hyaluronic acid, formulated to a concentration of 23 mg/ml in a physiologic buffer.
• Level of cross-linking 3/4.
• Cross-linking agent : BDDE (14%).
• Lidocaine 0,3%.
• OPTIMAL SKIN-TOLERANCE by use of non-animal hyaluronic acid.

INJECTION DEPTH

Injected in the deep dermis or subcutis.

DURATION

9 months.

INJECTION AREA

• Volume of cheekbones.
• Nasolabial fold.
• Wrinkles of the puppet.
• Chin.
• Facial depressive.

RESULTS

• TREATMENT SATISFACTION nearly 98% patients are satisfied with our products.
• IMMEDIATELY VISIBLE effectively after your treatment you see the result.
• LONG-LASTING RESULTS by formulation which shows an effect of severeal months.

SAYPHA Croma's range of hyaluronic acid fillers includes 6 products:

• SAYPHA RICH,
• SAYPHA FILLER (with / without lidocaine),
• SAYPHA VOLUME (with / without lidocaine) and
• SAYPHA VOLUME PLUS Lidocaine.

SAYPHA RICH (EC 0459)

• Regenerates the loss of hyaluronic acid due to aging, improves hydration, skin tone and elasticity and corrects fine lines.
• The product is injected into the superficial dermal layer.

SAYPHA FILLER (CE 0459) and SAYPHA FILLER Lidocaine (CE 0120)

• Corrects moderate to severe wrinkles and facial wrinkles and increases lip volume (only applicable for SAYPHA FILLER Lidocaine).
• The product is injected into the intermediate to deep dermis.

SAYPHA VOLUME (CE 0459) and SAYPHA VOLUME Lidocaine (EC 0120)

• Have been developed to correct deeper wrinkles and wrinkles and to restore facial volume / reshape facial contours.
• The product is injected into the deeper skin layer deep dermis or hypodermis.

SAYPHA VOLUME PLUS Lidocaine (EC 0120)

• Is used for facial tissue augmentation to correct lowering of the volume of the middle part of the face and to define the contours of the face as well as for reconstruction purposes, for example in the treatment of facial lipoatrophy.
• The product is injected subcutaneously, locally or in the deep dermis.
• All products are made from non-animal hyaluronic acid and are manufactured to the highest standards of quality and safety.

CROMA Pharma GmbH

Founded in 1976, CROMA-Pharma GmbH (Croma) is an Austrian family-owned company specializing in the industrial production of hyaluronic acid for the fields of aesthetic medicine, ophthalmology and orthopedics. CROMA currently manages 12 international sales companies and distributes its products in more than 70 countries. In its global sales network, CROMA focuses on its own brand products for minimally invasive cosmetic medicine. In addition to a wide range of hyaluronic acid-based fillers from its own production site, CROMA markets PDO tensor yarns, a Platelet Rich Plasma System (PRP) and customized skin care technology. within its core strategic markets.